| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry - paraffin section; mouse; 1:200; fig s7f
| Gupta A, Anjomani Virmouni S, Koundouros N, Dimitriadi M, Choo Wing R, Valle A, et al. PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation. Mol Cell. 2017;65:999-1013.e7 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; fig 2
| Wilkerson P, Dedes K, Samartzis E, Dedes I, Lambros M, Natrajan R, et al. Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. Oncotarget. 2017;8:6057-6066 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:50; fig 1
| Garcia Carracedo D, Villaronga M, Álvarez Teijeiro S, Hermida Prado F, Santamaria I, Allonca E, et al. Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas. Oncotarget. 2016;7:29780-93 pubmed publisher |
- immunohistochemistry - paraffin section; human; tbl 1
| Castillo Martin M, Thin T, Collazo Lorduy A, Cordon Cardo C. Immunopathologic Assessment of PTEN Expression. Methods Mol Biol. 2016;1388:23-37 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:50; fig 2
| Zaldumbide L, Erramuzpe A, Guarch R, Pulido R, Cortés J, López J. Snail heterogeneity in clear cell renal cell carcinoma. BMC Cancer. 2016;16:194 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 2
| Duchnowska R, Wysocki P, Korski K, Czartoryska Arłukowicz B, Niwińska A, Orlikowska M, et al. Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients. Oncotarget. 2016;7:550-64 pubmed publisher |
- immunohistochemistry; human; 1:100; loading ...; fig 3g
| Conde Perez A, Gros G, Longvert C, Pedersen M, Petit V, Aktary Z, et al. A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity. Nat Commun. 2015;6:8093 pubmed publisher |
- immunohistochemistry; human; 1:100
| Demicco E, Wani K, Fox P, Bassett R, Young E, Lev D, et al. Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations. Hum Pathol. 2015;46:1015-26 pubmed publisher |
- immunohistochemistry; human; 1:100
| Geels Y, van der Putten L, van Tilborg A, Lurkin I, Zwarthoff E, Pijnenborg J, et al. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium. Gynecol Oncol. 2015;137:245-51 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100
| Kong L, Wei J, Haider A, Liebelt B, Ling X, Conrad C, et al. Therapeutic targets in subependymoma. J Neuroimmunol. 2014;277:168-75 pubmed publisher |
- immunohistochemistry; human; tbl 2
| Eritja N, Santacana M, Maiques O, González Tallada X, Dolcet X, Matias Guiu X. Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model. Methods. 2015;77-78:31-40 pubmed publisher |
- immunohistochemistry; human; 1:100
| Cha Y, Han S, Seol H, Oh D, Im S, Bang Y, et al. Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Res. 2014;34:4275-80 pubmed |
- immunohistochemistry; mouse
| Costales M, Lopez F, García Inclán C, Fernandez S, Marcos C, Llorente J, et al. Establishment and characterization of an orthotopic sinonasal squamous cell carcinoma mouse model. Head Neck. 2015;37:1769-75 pubmed publisher |
- immunohistochemistry; human
| Melchor L, Molyneux G, Mackay A, Magnay F, Atienza M, Kendrick H, et al. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models. J Pathol. 2014;233:124-37 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:150
| Carvalho K, Maia B, Omae S, Rocha A, Covizzi L, Vassallo J, et al. Best practice for PTEN gene and protein assessment in anatomic pathology. Acta Histochem. 2014;116:25-31 pubmed publisher |
| Sizemore G, Balakrishnan S, Thies K, Hammer A, Sizemore S, TRIMBOLI A, et al. Stromal PTEN determines mammary epithelial response to radiotherapy. Nat Commun. 2018;9:2783 pubmed publisher |
| Richman S, Adams R, Quirke P, Butler R, Hemmings G, Chambers P, et al. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. J Clin Pathol. 2016;69:35-41 pubmed publisher |
| Knudsen K, Nielsen B, Lindebjerg J, Hansen T, Holst R, Sørensen F. microRNA-17 Is the Most Up-Regulated Member of the miR-17-92 Cluster during Early Colon Cancer Evolution. PLoS ONE. 2015;10:e0140503 pubmed publisher |
| Howitt B, Monte N, Elvin J, Mutter G. Dyssynchronous secretory endometrial glands often show sporadically acquired progesterone nonresponsiveness. Int J Gynecol Pathol. 2015;34:239-44 pubmed publisher |
| Green A, Barros F, Abdel Fatah T, Moseley P, Nolan C, Durham A, et al. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast Cancer Res Treat. 2014;145:33-44 pubmed publisher |
| Meyer S, Fuchs T, Bosserhoff A, Hofstadter F, Pauer A, Roth V, et al. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS ONE. 2012;7:e38222 pubmed publisher |
| Wild P, Ikenberg K, Fuchs T, Rechsteiner M, Georgiev S, Fankhauser N, et al. p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Mol Med. 2012;4:808-24 pubmed publisher |
